APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

GLP-1 Targeted Peptide Weight Loss Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

GLP-1 Targeted Peptide Weight Loss Drugs Industry Research Report 2026

Report ID 173995420527 December 2025146 pages

Choose your research edition.

Industry ResearchGLP-1 Targeted Peptide Weight Loss Drugs Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal GLP-1 Targeted Peptide Weight Loss Drugs Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal GLP-1 Targeted Peptide Weight Loss Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GLP-1 Targeted Peptide Weight Loss Drugs Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal GLP-1 Targeted Peptide Weight Loss Drugs Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global GLP-1 Targeted Peptide Weight Loss Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for GLP-1 Targeted Peptide Weight Loss Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for GLP-1 Targeted Peptide Weight Loss Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for GLP-1 Targeted Peptide Weight Loss Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of GLP-1 Targeted Peptide Weight Loss Drugs include Chugai Pharmaceutical, Benemae Pharmaceutical, Qilu Pharmaceutical, Jiuyuan Gene Engineering, Huadong Medicine, Zealand Pharma, The General Hospital Corp, Sanofi-Aventis and QuiaPEG Pharmaceuticals Ab, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global GLP-1 Targeted Peptide Weight Loss Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

GLP-1 Targeted Peptide Weight Loss Drugs Market by Company

Chugai Pharmaceutical

Benemae Pharmaceutical

Qilu Pharmaceutical

Jiuyuan Gene Engineering

Huadong Medicine

Zealand Pharma

The General Hospital Corp

Sanofi-Aventis

QuiaPEG Pharmaceuticals Ab

Orbis Biosciences

Novo Nordisk

Nano Precision Medical

Nanexa AB

Lexaria Bioscience

iX Biopharma

Intarcia Therapeutics

HIKMA PHARMS

Eli Lilly

Baxter Pharmaceutical

Astra Zeneca

Amylin Pharmaceuticals

GLP-1 Targeted Peptide Weight Loss Drugs Segment by Type

Oral

Injection

GLP-1 Targeted Peptide Weight Loss Drugs Segment by Application

Hospital

Clinic

Others

GLP-1 Targeted Peptide Weight Loss Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Targeted Peptide Weight Loss Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Targeted Peptide Weight Loss Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Targeted Peptide Weight Loss Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of GLP-1 Targeted Peptide Weight Loss Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of GLP-1 Targeted Peptide Weight Loss Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of GLP-1 Targeted Peptide Weight Loss Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global GLP-1 Targeted Peptide Weight Loss Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue of Manufacturers (2021-2026) Table 9. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market GLP-1 Targeted Peptide Weight Loss Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global GLP-1 Targeted Peptide Weight Loss Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of GLP-1 Targeted Peptide Weight Loss Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of GLP-1 Targeted Peptide Weight Loss Drugs, Product Type & Application Table 14. Global GLP-1 Targeted Peptide Weight Loss Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global GLP-1 Targeted Peptide Weight Loss Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Chugai Pharmaceutical Company Information Table 19. Chugai Pharmaceutical Business Overview Table 20. Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 22. Chugai Pharmaceutical Recent Developments Table 23. Benemae Pharmaceutical Company Information Table 24. Benemae Pharmaceutical Business Overview Table 25. Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 27. Benemae Pharmaceutical Recent Developments Table 28. Qilu Pharmaceutical Company Information Table 29. Qilu Pharmaceutical Business Overview Table 30. Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 32. Qilu Pharmaceutical Recent Developments Table 33. Jiuyuan Gene Engineering Company Information Table 34. Jiuyuan Gene Engineering Business Overview Table 35. Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 37. Jiuyuan Gene Engineering Recent Developments Table 38. Huadong Medicine Company Information Table 39. Huadong Medicine Business Overview Table 40. Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 42. Huadong Medicine Recent Developments Table 43. Zealand Pharma Company Information Table 44. Zealand Pharma Business Overview Table 45. Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 47. Zealand Pharma Recent Developments Table 48. The General Hospital Corp Company Information Table 49. The General Hospital Corp Business Overview Table 50. The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 52. The General Hospital Corp Recent Developments Table 53. Sanofi-Aventis Company Information Table 54. Sanofi-Aventis Business Overview Table 55. Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 57. Sanofi-Aventis Recent Developments Table 58. QuiaPEG Pharmaceuticals Ab Company Information Table 59. QuiaPEG Pharmaceuticals Ab Business Overview Table 60. QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 62. QuiaPEG Pharmaceuticals Ab Recent Developments Table 63. Orbis Biosciences Company Information Table 64. Orbis Biosciences Business Overview Table 65. Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 67. Orbis Biosciences Recent Developments Table 68. Novo Nordisk Company Information Table 69. Novo Nordisk Business Overview Table 70. Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 72. Novo Nordisk Recent Developments Table 73. Nano Precision Medical Company Information Table 74. Nano Precision Medical Business Overview Table 75. Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 77. Nano Precision Medical Recent Developments Table 78. Nanexa AB Company Information Table 79. Nanexa AB Business Overview Table 80. Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 82. Nanexa AB Recent Developments Table 83. Lexaria Bioscience Company Information Table 84. Lexaria Bioscience Business Overview Table 85. Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 87. Lexaria Bioscience Recent Developments Table 88. iX Biopharma Company Information Table 89. iX Biopharma Business Overview Table 90. iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 92. iX Biopharma Recent Developments Table 93. Intarcia Therapeutics Company Information Table 94. Intarcia Therapeutics Business Overview Table 95. Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 97. Intarcia Therapeutics Recent Developments Table 98. HIKMA PHARMS Company Information Table 99. HIKMA PHARMS Business Overview Table 100. HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 102. HIKMA PHARMS Recent Developments Table 103. Eli Lilly Company Information Table 104. Eli Lilly Business Overview Table 105. Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 107. Eli Lilly Recent Developments Table 108. Baxter Pharmaceutical Company Information Table 109. Baxter Pharmaceutical Business Overview Table 110. Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 112. Baxter Pharmaceutical Recent Developments Table 113. Astra Zeneca Company Information Table 114. Astra Zeneca Business Overview Table 115. Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 117. Astra Zeneca Recent Developments Table 118. Amylin Pharmaceuticals Company Information Table 119. Amylin Pharmaceuticals Business Overview Table 120. Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 122. Amylin Pharmaceuticals Recent Developments Table 123. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 124. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2021-2026) & (K Units) Table 125. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Region (2021-2026) Table 126. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2027-2032) & (K Units) Table 127. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Region (2027-2032) Table 128. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region (2021-2026) & (US$ Million) Table 129. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Region (2021-2026) Table 130. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region (2027-2032) & (US$ Million) Table 131. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Region (2027-2032) Table 132. North America GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026) & (K Units) Table 134. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2027-2032) & (K Units) Table 135. North America GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2021-2026) & (US$ Million) Table 136. North America GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2027-2032) & (US$ Million) Table 137. Europe GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026) & (K Units) Table 139. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2027-2032) & (K Units) Table 140. Europe GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2021-2026) & (US$ Million) Table 141. Europe GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2027-2032) & (US$ Million) Table 142. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026) & (K Units) Table 144. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2027-2032) & (K Units) Table 145. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2021-2026) & (US$ Million) Table 146. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2027-2032) & (US$ Million) Table 147. South America GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. South America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026) & (K Units) Table 149. South America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2027-2032) & (K Units) Table 150. South America GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2021-2026) & (US$ Million) Table 151. South America GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2027-2032) & (US$ Million) Table 152. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026) & (K Units) Table 154. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2027-2032) & (K Units) Table 155. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2021-2026) & (US$ Million) Table 156. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2027-2032) & (US$ Million) Table 157. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021-2026) & (K Units) Table 158. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2027-2032) & (K Units) Table 159. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Type (2021-2026) Table 160. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Type (2027-2032) Table 161. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Type (2021-2026) & (US$ Million) Table 162. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Type (2027-2032) & (US$ Million) Table 163. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Type (2021-2026) Table 164. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Type (2027-2032) Table 165. Global GLP-1 Targeted Peptide Weight Loss Drugs Price by Type (2021-2026) & (US$/Unit) Table 166. Global GLP-1 Targeted Peptide Weight Loss Drugs Price by Type (2027-2032) & (US$/Unit) Table 167. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021-2026) & (K Units) Table 168. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2027-2032) & (K Units) Table 169. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Application (2021-2026) Table 170. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Application (2027-2032) Table 171. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Application (2021-2026) & (US$ Million) Table 172. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Application (2027-2032) & (US$ Million) Table 173. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Application (2021-2026) Table 174. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Application (2027-2032) Table 175. Global GLP-1 Targeted Peptide Weight Loss Drugs Price by Application (2021-2026) & (US$/Unit) Table 176. Global GLP-1 Targeted Peptide Weight Loss Drugs Price by Application (2027-2032) & (US$/Unit) Table 177. Key Raw Materials Table 178. Raw Materials Key Suppliers Table 179. GLP-1 Targeted Peptide Weight Loss Drugs Distributors List Table 180. GLP-1 Targeted Peptide Weight Loss Drugs Customers List Table 181. GLP-1 Targeted Peptide Weight Loss Drugs Industry Trends Table 182. GLP-1 Targeted Peptide Weight Loss Drugs Industry Drivers Table 183. GLP-1 Targeted Peptide Weight Loss Drugs Industry Restraints Table 184. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. GLP-1 Targeted Peptide Weight Loss Drugs Product Image Figure 5. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales (2021-2032) & (K Units) Figure 8. Global GLP-1 Targeted Peptide Weight Loss Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. Oral Product Image Figure 10. Injection Product Image Figure 11. Hospital Product Image Figure 12. Clinic Product Image Figure 13. Others Product Image Figure 14. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of GLP-1 Targeted Peptide Weight Loss Drugs, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 GLP-1 Targeted Peptide Weight Loss Drugs Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region in 2025 Figure 20. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region in 2025 Figure 21. North America GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country in 2025 Figure 22. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2021-2032) Figure 23. North America GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Country (2021-2032) Figure 24. United States GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country in 2025 Figure 28. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2021-2032) Figure 29. Europe GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Country (2021-2032) Figure 30. Germany GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country in 2025 Figure 41. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Country (2021-2032) Figure 43. China GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country in 2025 Figure 52. South America GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2021-2032) Figure 53. South America GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Country (2021-2032) Figure 54. Brazil GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country in 2025 Figure 58. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Country (2021-2032) Figure 60. Egypt GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries GLP-1 Targeted Peptide Weight Loss Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Type (2021-2032) Figure 66. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Type (2021-2032) Figure 67. Global GLP-1 Targeted Peptide Weight Loss Drugs Price (US$/Unit) by Type (2021-2032) Figure 68. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Application (2021-2032) Figure 69. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Application (2021-2032) Figure 70. Global GLP-1 Targeted Peptide Weight Loss Drugs Price (US$/Unit) by Application (2021-2032) Figure 71. GLP-1 Targeted Peptide Weight Loss Drugs Value Chain Figure 72. GLP-1 Targeted Peptide Weight Loss Drugs Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. GLP-1 Targeted Peptide Weight Loss Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Chugai Pharmaceutical
  • Benemae Pharmaceutical
  • Qilu Pharmaceutical
  • Jiuyuan Gene Engineering
  • Huadong Medicine
  • Zealand Pharma
  • The General Hospital Corp
  • Sanofi-Aventis
  • QuiaPEG Pharmaceuticals Ab
  • Orbis Biosciences
  • Novo Nordisk
  • Nano Precision Medical
  • Nanexa AB
  • Lexaria Bioscience
  • iX Biopharma
  • Intarcia Therapeutics
  • HIKMA PHARMS
  • Eli Lilly
  • Baxter Pharmaceutical
  • Astra Zeneca
  • Amylin Pharmaceuticals

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size (2021-2032)
  4. 2.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales (2021-2032)
  5. 2.2.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Average Price (2021-2032)
  6. 2.3 GLP-1 Targeted Peptide Weight Loss Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Oral
  9. 2.3.3 Injection
  10. 2.4 GLP-1 Targeted Peptide Weight Loss Drugs by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital
  13. 2.4.3 Clinic
  14. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global GLP-1 Targeted Peptide Weight Loss Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global GLP-1 Targeted Peptide Weight Loss Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of GLP-1 Targeted Peptide Weight Loss Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of GLP-1 Targeted Peptide Weight Loss Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of GLP-1 Targeted Peptide Weight Loss Drugs, Established Date
  9. 3.9 Global GLP-1 Targeted Peptide Weight Loss Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Chugai Pharmaceutical
  2. 4.1.1 Chugai Pharmaceutical Company Information
  3. 4.1.2 Chugai Pharmaceutical Business Overview
  4. 4.1.3 Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  6. 4.1.5 Chugai Pharmaceutical Recent Developments
  7. 4.2 Benemae Pharmaceutical
  8. 4.2.1 Benemae Pharmaceutical Company Information
  9. 4.2.2 Benemae Pharmaceutical Business Overview
  10. 4.2.3 Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  12. 4.2.5 Benemae Pharmaceutical Recent Developments
  13. 4.3 Qilu Pharmaceutical
  14. 4.3.1 Qilu Pharmaceutical Company Information
  15. 4.3.2 Qilu Pharmaceutical Business Overview
  16. 4.3.3 Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  18. 4.3.5 Qilu Pharmaceutical Recent Developments
  19. 4.4 Jiuyuan Gene Engineering
  20. 4.4.1 Jiuyuan Gene Engineering Company Information
  21. 4.4.2 Jiuyuan Gene Engineering Business Overview
  22. 4.4.3 Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  24. 4.4.5 Jiuyuan Gene Engineering Recent Developments
  25. 4.5 Huadong Medicine
  26. 4.5.1 Huadong Medicine Company Information
  27. 4.5.2 Huadong Medicine Business Overview
  28. 4.5.3 Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  30. 4.5.5 Huadong Medicine Recent Developments
  31. 4.6 Zealand Pharma
  32. 4.6.1 Zealand Pharma Company Information
  33. 4.6.2 Zealand Pharma Business Overview
  34. 4.6.3 Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  36. 4.6.5 Zealand Pharma Recent Developments
  37. 4.7 The General Hospital Corp
  38. 4.7.1 The General Hospital Corp Company Information
  39. 4.7.2 The General Hospital Corp Business Overview
  40. 4.7.3 The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  42. 4.7.5 The General Hospital Corp Recent Developments
  43. 4.8 Sanofi-Aventis
  44. 4.8.1 Sanofi-Aventis Company Information
  45. 4.8.2 Sanofi-Aventis Business Overview
  46. 4.8.3 Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  48. 4.8.5 Sanofi-Aventis Recent Developments
  49. 4.9 QuiaPEG Pharmaceuticals Ab
  50. 4.9.1 QuiaPEG Pharmaceuticals Ab Company Information
  51. 4.9.2 QuiaPEG Pharmaceuticals Ab Business Overview
  52. 4.9.3 QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  54. 4.9.5 QuiaPEG Pharmaceuticals Ab Recent Developments
  55. 4.10 Orbis Biosciences
  56. 4.10.1 Orbis Biosciences Company Information
  57. 4.10.2 Orbis Biosciences Business Overview
  58. 4.10.3 Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  60. 4.10.5 Orbis Biosciences Recent Developments
  61. 4.11 Novo Nordisk
  62. 4.11.1 Novo Nordisk Company Information
  63. 4.11.2 Novo Nordisk Business Overview
  64. 4.11.3 Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  66. 4.11.5 Novo Nordisk Recent Developments
  67. 4.12 Nano Precision Medical
  68. 4.12.1 Nano Precision Medical Company Information
  69. 4.12.2 Nano Precision Medical Business Overview
  70. 4.12.3 Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  72. 4.12.5 Nano Precision Medical Recent Developments
  73. 4.13 Nanexa AB
  74. 4.13.1 Nanexa AB Company Information
  75. 4.13.2 Nanexa AB Business Overview
  76. 4.13.3 Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  78. 4.13.5 Nanexa AB Recent Developments
  79. 4.14 Lexaria Bioscience
  80. 4.14.1 Lexaria Bioscience Company Information
  81. 4.14.2 Lexaria Bioscience Business Overview
  82. 4.14.3 Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  84. 4.14.5 Lexaria Bioscience Recent Developments
  85. 4.15 iX Biopharma
  86. 4.15.1 iX Biopharma Company Information
  87. 4.15.2 iX Biopharma Business Overview
  88. 4.15.3 iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  90. 4.15.5 iX Biopharma Recent Developments
  91. 4.16 Intarcia Therapeutics
  92. 4.16.1 Intarcia Therapeutics Company Information
  93. 4.16.2 Intarcia Therapeutics Business Overview
  94. 4.16.3 Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  96. 4.16.5 Intarcia Therapeutics Recent Developments
  97. 4.17 HIKMA PHARMS
  98. 4.17.1 HIKMA PHARMS Company Information
  99. 4.17.2 HIKMA PHARMS Business Overview
  100. 4.17.3 HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  102. 4.17.5 HIKMA PHARMS Recent Developments
  103. 4.18 Eli Lilly
  104. 4.18.1 Eli Lilly Company Information
  105. 4.18.2 Eli Lilly Business Overview
  106. 4.18.3 Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  108. 4.18.5 Eli Lilly Recent Developments
  109. 4.19 Baxter Pharmaceutical
  110. 4.19.1 Baxter Pharmaceutical Company Information
  111. 4.19.2 Baxter Pharmaceutical Business Overview
  112. 4.19.3 Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  114. 4.19.5 Baxter Pharmaceutical Recent Developments
  115. 4.20 Astra Zeneca
  116. 4.20.1 Astra Zeneca Company Information
  117. 4.20.2 Astra Zeneca Business Overview
  118. 4.20.3 Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  120. 4.20.5 Astra Zeneca Recent Developments
  121. 4.21 Amylin Pharmaceuticals
  122. 4.21.1 Amylin Pharmaceuticals Company Information
  123. 4.21.2 Amylin Pharmaceuticals Business Overview
  124. 4.21.3 Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  126. 4.21.5 Amylin Pharmaceuticals Recent Developments
5 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Scenario by Region
  1. 5.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region: 2027-2032
  5. 5.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Region: 2027-2032
  8. 5.4 North America GLP-1 Targeted Peptide Weight Loss Drugs Market Facts & Figures by Country
  9. 5.4.1 North America GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Facts & Figures by Country
  16. 5.5.1 Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2032)
  18. 5.5.3 Europe GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America GLP-1 Targeted Peptide Weight Loss Drugs Market Facts & Figures by Country
  41. 5.7.1 South America GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2032)
  43. 5.7.3 South America GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 GLP-1 Targeted Peptide Weight Loss Drugs Value Chain Analysis
  2. 8.1.1 GLP-1 Targeted Peptide Weight Loss Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 GLP-1 Targeted Peptide Weight Loss Drugs Production Mode & Process
  5. 8.2 GLP-1 Targeted Peptide Weight Loss Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 GLP-1 Targeted Peptide Weight Loss Drugs Distributors
  8. 8.2.3 GLP-1 Targeted Peptide Weight Loss Drugs Customers
9 Global GLP-1 Targeted Peptide Weight Loss Drugs Analyzing Market Dynamics
  1. 9.1 GLP-1 Targeted Peptide Weight Loss Drugs Industry Trends
  2. 9.2 GLP-1 Targeted Peptide Weight Loss Drugs Industry Drivers
  3. 9.3 GLP-1 Targeted Peptide Weight Loss Drugs Industry Opportunities and Challenges
  4. 9.4 GLP-1 Targeted Peptide Weight Loss Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst